knowledge -WSS

knowledge

author：hotspot 2025-09-27 09:59:15 - browse：99748

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Did you have Obamacare on your GOP debate bingo card?

WSS

Biogen shutters digital health group, ends Apple study, in cost cutting move

Covid vaccines: Private market messier than government rollout

Medicare drug price negotiation program allowed for now

Future doctors should be trained to promote social change

Nurses recount patients attacks

SCOTUS questions limit to govt efforts to fight misinformation

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Bright Health sells Medicare Advantage business to Molina

Data show record exodus of life scientists from academia

The high cost of giving birth even with insurance

Mindstrong's demise and the future of mental health care

New air purifier tech could be key to improving indoor air quality

Medicaid, Medicare dual

In age of alternative facts, a scholarly course on calling out crap

Nurses recount patients attacks

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Mindstrong's demise and the future of mental health care

explore

Biogen shutters digital health group, ends Apple study, in cost cutting move

Listen: Who gets the credit for GLP

How the Dana

Gene editing the human germline: What are the risks?

Data show record exodus of life scientists from academia

Physicians and social media: If you see something, say something?

explore

knowledge

hotspot

focus